S

Synthaverse SA
WSE:SVE

Watchlist Manager
Synthaverse SA
WSE:SVE
Watchlist
Price: 4.14 PLN -2.47% Market Closed
Market Cap: 293m PLN
Have any thoughts about
Synthaverse SA?
Write Note

Operating Margin
Synthaverse SA

11.8%
Current
17%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.8%
=
Operating Profit
6.8m
/
Revenue
57.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
PL
Synthaverse SA
WSE:SVE
292m PLN
12%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
314.9B USD
28%
US
Amgen Inc
NASDAQ:AMGN
140.6B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.9B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
135.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.8B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country PL
Market Cap 292m PLN
Operating Margin
12%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 314.9B USD
Operating Margin
28%
Country US
Market Cap 140.6B USD
Operating Margin
19%
Country US
Market Cap 115.7B USD
Operating Margin
38%
Country US
Market Cap 103.9B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 135.7B AUD
Operating Margin
26%
Country US
Market Cap 77.8B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Synthaverse SA
Glance View

Market Cap
292m PLN
Industry
Biotechnology

Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 234 full-time employees. The company went IPO on 2011-07-29. The firm focuses on the production of drugs in the field of immunotherapy. Synthaverse SA offers its services in the field such as: oncological immunotherapy, Immunotherapy in Serological Conflict, Passive immunotherapy in hepatitis B, Active anti-tuberculosis immunotherapy, Gynecology and Proctology, Probiotics, Laboratory reagents. The firm offers injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, suppository forms of drugs. The firm supplies its products to 50 countries around the world.

SVE Intrinsic Value
6.95 PLN
Undervaluation 40%
Intrinsic Value
Price
S

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
11.8%
=
Operating Profit
6.8m
/
Revenue
57.4m
What is the Operating Margin of Synthaverse SA?

Based on Synthaverse SA's most recent financial statements, the company has Operating Margin of 11.8%.